Ironwood Pharmaceuticals' Pediatric Constipation Treatment Gets FDA Approval
12 Junho 2023 - 5:54PM
Dow Jones News
By Sabela Ojea
Ironwood Pharmaceuticals said Monday that the U.S. Food and Drug
Administration has granted approval to its Linzess treatment for
pediatric patients with functional constipation.
The pharmaceutical company said Linzess has been approved for
patients aged six to 17 years-old following the results of a large,
multicenter, double-blind, phase 3 study.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
June 12, 2023 16:39 ET (20:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
